[ad_1]
The clinical value and significance of the ‘DAPA-HF study’ for the treatment of chronic heart failure
More than half of heart failure patients died within 5 years … Growing demand for new treatment options
Decrease in heart failure, risk of cardiovascular death by 26% … helping to improve quality of life
Chronic heart failure has a high patient burden and a high mortality rate, as it can be said to be the end of heart disease. The disease is difficult to improve and repeated hospitalization and discharge have a significant impact on the quality of life of patients. Furthermore, the number of patients is expected to increase even more as we enter the ultra-aged society.
In December last year, the first SGLT-2 inhibitor-based treatment for type 2 diabetes was prepared to examine the clinical significance of ‘Possiga’ (ingredient name: dapagliflozin), which added an indication for the treatment of chronic heart failure.
On the 25th, AstraZeneca Korea held an online conference to present the clinical value and efficacy of Posiga’s heart failure treatment, confirmed through the DAPA-HF study.
The meeting was held by Choi Dong-ju, President of the Korean Heart Failure Society (Professor at Seoul Medical University, Seoul National University Bundang Hospital), and Professor Jin-oh Choi (Director of Cardiology Research and Korean Heart Failure Society, Samsung Medical Center), ‘Heart Failure Disease Introduction and Treatment Goals’, Professor Seong-Hoon Choi (Academic Director of Cardiovascular Internal Medicine, Gangnam Cardiology Hospital, Korean Heart Failure Society) , ‘Efficacy and Safety of Posiga’s Heart Failure Treatment by DAPA-HF Study’, Professor Kim Eung-ju, Korea Medical University (Cardiovascular Center, Korea Daeguro Hospital, General Secretary Director) led a series of presentations such as’ Management of concomitant diseases in patients with heart failure ‘and Questions and answers.
Professor Jin-oh Choi cited the prevention of hospitalization and the reduction of the mortality rate, the management of comorbid diseases and the improvement of the clinical condition, the improvement of the patient’s range of function, and the quality of life as considerations for the treatment of heart failure, as the prevalence and medical cost of Heart failure in Korea continues to rise, and stressed the importance of applying the optimal treatment.
Professor Choi said: “Despite standard treatment, the survival rate is low enough that more than half of patients diagnosed with heart failure die within 5 years, and efforts are needed to further reduce the rates of heart failure. death and hospitalization due to heart failure and reduce costs. ” He expressed his expectations about the option.
Awareness about the treatment of heart failure was also increased.
Professor Choi said: “When you first visit the hospital for symptoms of heart failure, such as shortness of breath, using diuretics alone can improve symptoms. However, even if symptoms improve, the disease eventually progresses. appropriate treatment so that the disease does not progress. It is necessary to recognize that progress can be improved after receiving the patient. In addition, it is necessary to increase the awareness of heart failure disease so that the patient has more opportunities to receive treatment. ” : “I hope you pay more attention to the hospital. If you see abnormal findings such as X-rays or EKGs, you should suspect heart failure. BNP blood tests that use biomarkers are also helpful. You must also report the diagnostic method “..”
Professor Seong-Hoon Choi, who led the second presentation, said Posiga confirmed the benefits of hospitalization for heart failure and prevention of cardiovascular death in the DECLARE study of patients with type 2 diabetes. deaths from cardiovascular disease o Worsening heart failure was reduced in patients with reduced chronic heart failure.
Professor Choi said: “Among the results of the DAPA-HF study, the most significant part of this study is that the risk of death from worsening heart failure and cardiovascular disease was reduced by 26% in patients already receiving the standard treatment for heart failure. “In a study that evaluated improvement of symptoms and quality of life through outcomes, Fossiga improved the KCCQ score (Kansas City Cardiomyopathy Questionnaire, University of Kansas Cardiomyopathy Questionnaire)” .
Professor Choi said: “Regardless of the presence of diabetes, the standard treatment of heart failure remains stable in patients with heart failure with left ventricular ejection frequency (HFrEF), and in patients with added dapagliflozin, cardiovascular accidents and readmissions for heart failure, as well as mortality, are confirmed and adverse reactions caused by drug use did not increase and were used safely. “
It is noted that the use of SGLT2 inhibitors is recommended for patients with recent cardiovascular disease or patients with high-risk diabetes, and it is strongly recommended as the main drug to reduce deaths and readmissions, especially in patients with HF-FEr.
Finally, Prof. Eung-Joo Kim, who presented the topic ‘Management of Concomitant Diseases in Patients with Heart Failure’, in the DECLARE study, addresses type 2 diabetics (eGFR 60mL / min / 1.73m2 or more). /Min/1.73 m2, continuous reduction, death from end-stage renal failure or kidney disease) by 47% In addition, the DAPA-HF study also showed a group of patients with chronic heart failure with reduced left ventricular contractile function (eGFR 30 ml / min / He explained that the target renal complex variable (eGFR of at least 50% or more, death from end-stage renal failure or kidney disease) also showed a 29% decreasing trend and showed the effect of treating heart failure regardless of the patient’s situation.Renal function.
Professor Kim said: “As kidney function deteriorates in heart failure patients, the risk of hospitalization and death from heart failure increases. Therefore, it is important to check the data related to the kidneys in cardiology in terms of management of comorbidities “. He highlighted that the rate of the disease was reduced by 59% and the risk of dialysis patients was reduced by 69% ”. “Chronic kidney disease has a greater effect on death from heart failure than anemia and diabetes,” he said. “Diabetes itself has a negative effect on cardiovascular and heart failure, but because Foscigar has been shown to be effective in patients with diabetes, it also prevents the progression of diabetes. It is significant because it can help with cardiovascular and kidney disease.”
Professor Choi Dong-ju, who held a meeting as moderator, said: “Since heart failure is a disease with a low survival rate, the emergence of new treatment options is of great importance.” “If the results are confirmed through Posiga’s clinical research.” apply to the actual treatment environment. It is expected to go a long way toward improving the survival rate of heart failure patients. “” Later this month, a new guideline for the treatment of heart failure will be released at the American Heart Association. ” he emphasized “There are good drugs without setting steps 1, 2 and 3 as standard treatments, and there is a tendency to use them immediately.
Shim Il, Managing Director of AstraZeneca Korea (CVRM Division), said: “AstraZeneca proclaimed the ‘CaReMe (Cardiovascular, Renal, Metabolism)’ vision in 2018, promoting an integrated approach to endocrine cardiovascular and kidney diseases, and suffering from multiple diseases We have constantly strived to address unmet patient needs and ultimately improve treatment outcomes and reduce mortality, “he said.” As the first SGLT-2 inhibitor to acquire the indication for the treatment of chronic heart failure, we hope will contribute to the innovative shift of the heart failure treatment paradigm. I hope so, “he added.
Copyright holder © Uihyeop Shinmun Unauthorized reproduction and redistribution prohibited
